Le Lézard
Classified in: Health, Science and technology, Business
Subjects: CXP, SRI

Turn Biotechnologies' Expands eTurnatm Delivery Platform to Solve Delivery and Targeting Issues that Challenge Industry


MOUNTAIN VIEW, Calif., Jan. 3, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and enabling technologies, today announced the expansion of its eTurnatm delivery platform that is expected to overcome the greatest challenge to breakthrough therapies: The safe and efficient targeting of specific organs and cells.

The significant expansion allows for infinite customization options for nucleic acid cargo and can be optimized for other cargoes and various routes of administration to target specific organs, tissues and cells.

The proprietary ionizable lipids used in the eTurnatm delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading. Since the platform can utilize PEG-free stabilizing components, the delivery system minimizes or eliminates immunogenicity associated with PEG lipids currently used in LNPs. The platform's optimized particle size also means higher transfection rates for the therapies it delivers.

"Our eTurnatm delivery platform offers a solution to the biggest problem therapeutic developers face worldwide: Finding the optimal vehicle to deliver their breakthrough therapies precisely to the target tissue with the ideal dosage ? and doing all this safely," said Turn Bio CEO Anja Krammer. "It is designed to enable the delivery of therapies to treat incurable diseases by targeting cells that medicine cannot currently reach.

"We are developing this breakthrough delivery platform to take our therapies to the clinic, but eTurna offers promise to other researchers developing different treatments as well," she said.

Turn Bio's first drug candidates are focused on treating the skin by targeting specific cells including fibroblasts, endothelial cells and keratinocytes. The eTurna delivery platform has also been found effective in delivering mRNA in blood cells, such as T cells and macrophages, and shows promise in bringing therapies to virtually any organ, tissue or cell with its library of formulations.

ABOUT TURN BIOTECHNOLOGIES

Turn Bio is a pre-clinical-stage company focused on repairing tissue at the cellular level and developing transformative drug delivery systems. The company's proprietary mRNA-based ERAtm reprogramming technology restores optimal gene expression by combatting the effects of aging in the epigenome. This restores cells' ability to prevent or treat disease and heal or regenerate tissue. It will help to fight incurable chronic diseases. Its eTurnatm delivery platform uses unique formulations to precisely deliver cargo to specific organs, tissues, and cell types.

The company is completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, and developing therapies for ophthalmology, osteo-arthritis, and the muscular system. For more information, see www.turn.bio.

FOR MORE INFORMATION, CONTACT:

Jim Martinez, rightstorygroup
[email protected] or (312) 543-9026

SOURCE Turn Biotechnologies


These press releases may also interest you

at 12:35
The United Steelworkers union (USW) strongly condemns the U.S. President Donald Trump plan to impose 25% tariffs on all steel and aluminum imports. These unjustified measures threaten thousands of Canadian jobs, disrupt supply chains and undermine...

at 12:35
Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Metals & Mining Virtual Investor Conference to be held February 12th & 13th. Individual investors, institutional investors, advisors, and...

at 12:33
Barre3, a wellness brand renowned for its dedication to women's fitness has acquired San Diego based barre brand, Studio Barre. Their 11 studios across California, Montana, Rhode Island and South Carolina will all become barre3. Founded in 2008 by...

at 12:30
CN and Tree Canada have awarded ten Canadian communities with $50,000 grants for tree planting and greening projects. These grants, totaling $500,000, are made possible through CN EcoConnexions ? From the Ground Up program that invests in community...

at 12:26
Summit Materials, Inc. ("Summit," "Summit Materials" or the "Company"), a leading producer of aggregates and cement, today announced the closing of its previously announced definitive agreement to be acquired by Quikrete Holdings, Inc. ("Quikrete")...

at 12:26
Crunch Fitness today announces the grand opening of Crunch Myrtle Beach in Myrtle Beach, South Carolina. The $3 million state-of-the-art fitness facility will be having its grand opening party on February 11, 2025. Operated by Crunch Fitness...



News published on and distributed by: